Information for Shareholders and Investors

We have created this section for our shareholders and investors as proof of our commitment to transparency.

This section includes all of the information required under the applicable legislation in this connection, as well as additional information deemed relevant for investors.

Corporate profile

Founded in 2000 in Barcelona, Spain, Oryzon Genomics, S.A. (ISIN Code: ES0167733015) (“Oryzon”) is a clinical stage biopharmaceutical company considered as the European champion in Epigenetics. The company leverages epigenetics to discover and develop innovative personalized therapeutics for diseases with a strong unmet medical need, with a particular focus in oncology and CNS diseases.

Oryzon has one of the strongest portfolios in the field. Oryzon’s LSD1 program has rendered two compounds in clinical trials: iadademstat and vafidemstat, both currently in Phase II. In addition, Oryzon has ongoing programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases.

Oryzon has offices in Spain and the United States.

Corporate Presentation

Please contact us for investor information.

Telf: (+34) 93 707 4100

Subscribe to our mailing list and stay up to date with our latest news